InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-46.4%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Lamstein Joshua R, Président. Insider active across 1 company, notably Scopus BioPharma Inc.. Aggregated, 6 filings have been logged. Breakdown: 6 buys · 0 sell. Total volume traded: €19k. History available since 23 July 2021. The latest transaction was disclosed on 26 August 2021 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
200 shares@ US$4.903.30% mcap4.3% of flowCommon Stock, par value $0.001SEC:0001104659-21-110652:0
Ideal exit: 23 May 2022 (T+270)
200 shares@ US$4.904.3% of flowCommon Stock, par value $0.001SEC:0001104659-21-110652
Ideal exit: 23 May 2022 (T+270)
800 shares@ US$4.0410.96% mcap14.4% of flowCommon Stock, par value $0.001SEC:0001104659-21-108657:0
Ideal exit: 16 May 2022 (T+270)
800 shares@ US$4.0414.4% of flowCommon Stock, par value $0.001SEC:0001104659-21-108657
Ideal exit: 16 May 2022 (T+270)
1,500 shares@ US$4.7131.2% of flowCommon Stock, par value $0.001SEC:0001104659-21-096342
Ideal exit: 19 Apr 2022 (T+270)
1,500 shares@ US$4.7123.77% mcap31.2% of flowCommon Stock, par value $0.001SEC:0001104659-21-096342:0
Ideal exit: 19 Apr 2022 (T+270)
6 of 6 declarations
About Lamstein Joshua R
Joshua R. Lamstein serves as Chairman of Scopus BioPharma Inc. In this role, he oversees the activities of the board of directors and contributes to the strategic direction of the company. Joshua brings valuable experience in the biopharmaceutical sector, enabling him to assess growth and innovation opportunities. His role is crucial in ensuring compliance and transparency in governance.
